Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin.
Liu, X., Onda, M., Watson, N., Hassan, R., Ho, M., Bera, T.K., Wei, J., Chakraborty, A., Beers, R., Zhou, Q., Shajahan, A., Azadi, P., Zhan, J., Xia, D., Pastan, I.(2022) Proc Natl Acad Sci U S A 119: e2202439119-e2202439119
- PubMed: 35512094 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1073/pnas.2202439119
- Primary Citation Related Structures: 
7U8C - PubMed Abstract: 
SignificanceMesothelin (MSLN) is a cell-surface protein that is a popular target for antibody-based therapies. We have identified shed MSLN as a major obstacle to successful antibody therapies and prepared a monoclonal antibody that inhibits shedding and makes very active CAR T cells whose activity is not blocked by shed MSLN and merits further preclinical development.
- Laboratory of Molecular Biology, National Cancer Institute (NCI), Bethesda, MD 20892-4264.
Organizational Affiliation: 


















